CALGARY, Nov. 8 /PRNewswire-FirstCall/ – Dr. Brad Thompson, President and
CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a
corporate overview of the Company at the BIO-Europe 2007 13th Annual
International Partnering Conference on Tuesday, November 13, 2007. The event
is being held at the CCH-Congress Center, Hamburg, Germany from November
12-14, 2007.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics’
clinical program includes a variety of Phase I and Phase II human trials using
REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
The presentation times are subject to change. This release and the
presentation related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company’s control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company’s quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward- looking statements.
SOURCE Oncolytics Biotech Inc.
Released November 8, 2007